These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24636673)

  • 1. Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial.
    Estol CJ; Bath PM; Gorelick PB; Cotton D; Martin RH;
    Int J Stroke; 2014 Oct; 9 Suppl A100():43-7. PubMed ID: 24636673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study.
    Estol CJ; Bath PM; Gorelick PB; Cotton D; Martin RH; Weber MA; Dahlof B; ;
    Blood Press Monit; 2014 Oct; 19(5):256-62. PubMed ID: 24736279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW;
    N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
    Diener HC; Sacco RL; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW;
    Lancet Neurol; 2008 Oct; 7(10):875-84. PubMed ID: 18757238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PRoFESS trial: future impact on secondary stroke prevention.
    Diener HC
    Expert Rev Neurother; 2007 Sep; 7(9):1085-91. PubMed ID: 17868007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
    Alvarez-Sabín J; Quintana M; Santamarina E; Maisterra O
    Cerebrovasc Dis; 2014; 37(3):181-7. PubMed ID: 24503927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.
    Weber R; Weimar C; Blatchford J; Hermansson K; Wanke I; Möller-Hartmann C; Gizewski ER; Forsting M; Demchuk AM; Sacco RL; Saver JL; Warach S; Diener HC; Diehl A;
    Stroke; 2012 Sep; 43(9):2336-42. PubMed ID: 22738922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
    Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Weber R; Weimar C; Wanke I; Möller-Hartmann C; Gizewski ER; Blatchford J; Hermansson K; Demchuk AM; Forsting M; Sacco RL; Saver JL; Warach S; Diener HC; Diehl A;
    Stroke; 2012 Feb; 43(2):350-5. PubMed ID: 22267825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
    Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
    Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    Ovbiagele B; Diener HC; Yusuf S; Martin RH; Cotton D; Vinisko R; Donnan GA; Bath PM;
    JAMA; 2011 Nov; 306(19):2137-44. PubMed ID: 22089721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis.
    Bath PM; Martin RH; Palesch Y; Cotton D; Yusuf S; Sacco R; Diener HC; Toni D; Estol C; Roberts R;
    Stroke; 2009 Nov; 40(11):3541-6. PubMed ID: 19797187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 17. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
    White CL; Szychowski JM; Roldan A; Benavente MF; Pretell EJ; Del Brutto OH; Kase CS; Arauz A; Meyer BC; Meissner I; Demaerschalk BM; McClure LA; Coffey CS; Pearce LA; Conwit R; Irby LH; Peri K; Pergola PE; Hart RG; Benavente OR;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):764-74. PubMed ID: 22516427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.